Citations

Showing 10 of 108119 citations.

Maximizing quality of life remains an ultimate goal in the era of precision medicine: exemplified by lung cancer
Yang, Ping

Mayo Clinic

Precision Clinical Medicine | March 11, 2019 | Volume: 2 | Issue: 1 | Pages: 8-12

10.1093/pcmedi/pbz001 | PMID 35694702 Get It

Abstract An ultimate goal of precision medicine in lung cancer treatment is to restore patient health with maximized quality of life (QOL). Results from Mayo Clinic studies show that a significant improvement in fatigue, dyspnea, and pain scales could lead to better overall QOL. Although treatments and guidelines for clinical implementation to alleviate these key symptoms are available, few cancer patients receive adequate therapy, mostly because of limitations in current care delivery systems and unclear clinicians’ roles. For optimal care of lung cancer survivors in different subpopulations, three barriers must be overcome: physicians’ lack of knowledge, unwarranted practice variation, and uncertainty regarding care provider roles. Appropriate culturally adapted, tested and validated tools for QOL measures must be developed, rather than directly translating existing tools between different languages and across cultures or diverse subpopulations. Finally, lack of sensitive, adequate, and relevant tools in measuring health-related QOL (HRQOL) has long been an issue for effective data collection, demanding a global consensus on a set of core components that reflect the needs of all critical parties for the best cure and care, supporting patients to achieve optimal HRQOL.
Clinical Experience with Rituximab and Intravenous Immunoglobulin for Pretibial Myxedema: A Case Series
Kotwal, Anupam , Sonawane, Vikram, Bahn, Rebecca S. , Pittelkow, Mark R. , Bridges, Alina G. , Stan, Marius N. , Bridges, Alina, Kudva, Yogish C , Stan, Marius N , Turcu, Adina F.

Mayo Clinic

Thyroid® | March 11, 2019 | Volume: 29 | Issue: 5 | Pages: 692-699

10.1089/thy.2018.0706 | PMID 30854936 Get It

Background: Severe pretibial myxedema (PTM) can be difficult to manage, highlighting the need to investigate newer therapies. Rituximab (RTX) and intravenous immunoglobulin (IVIg) have been tried in Graves' orbitopathy. Since PTM and orbitopathy share a similar underlying pathophysiology, this study aimed to explore these therapies for progressive PTM. Methods: The electronic database was screened for PTM patients evaluated at the Mayo Clinic, Rochester, from 2002 to 2016, and three patients who received IVIg and five who received RTX are reported. PTM pattern was classified as non-pitting edema, plaque and induration, nodular/nummular, and elephantiasis. PTM was confirmed by biopsy in six patients. Results: The patients' median age was 53.8 years, 75% were female, and all but one patient were either active or former smokers. All patients were euthyroid and had progressed despite various therapies prior to starting these agents. Six patients had a plaque and induration pattern, and two had a nodular pattern with elephantiasis. After therapy, six (75%) patients had PTM stability or improvement both subjectively and objectively (80% with RTX and 66% with IVIg). The three patients (one in the IVIg group and two in the RTX group) who had subjective improvement had a plaque pattern. One patient with elephantiasis had a transient response to IVIg and another had stability after RTX. Thyrotropin receptor antibody values and orbitopathy also improved in patients who demonstrated PTM improvement. No serious adverse events were reported, but one patient each had transient hypertension and injection-site thrombophlebitis after IVIg. Conclusions: Immunomodulation therapy was followed by PTM improvement or stability in most patients, with a slightly better response after RTX compared to IVIg. A validated response assessment instrument and larger series of patients are required to determine if the underlying disease process could be curtailed with these agents.
Attendee’s Perspective of the Medical Students Interested in Plastic Surgery Day at The Aesthetic Meeting
Oliver, Jeremie D. , Oliver, Jeremie D

Mayo Clinic

Aesthetic Surgery Journal | March 10, 2019 | Volume: 39 | Issue: 5 | Pages: NP159-NP160

10.1093/asj/sjz047 | PMID 30854551 Get It

Aged‐senescent cells contribute to impaired heart regeneration
Lewis, Fiona , Domenjo‐Vila, Eva , Teoh, Tze Shin , Prata, Larissa , Cottle, Beverley J. , Clark, James , Punjabi, Prakash P , Kirkland, James L. , Ellison, Georgina M. , Tchkonia, Tamara, Prata, Larissa G P Langhi , Ellison-Hughes, Georgina M , Ruchaya, Prashant Jay , Awad, Wael Ibrahim , Torella, Daniele , Tchkonia, Tamar

Mayo Clinic

Aging Cell | March 10, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12931 | PMID 30854802 Get It

Abstract Aging leads to increased cellular senescence and is associated with decreased potency of tissue‐specific stem/progenitor cells. Here, we have done an extensive analysis of cardiac progenitor cells (CPCs) isolated from human subjects with cardiovascular disease, aged 32–86 years. In aged subjects (>70 years old), over half of CPCs are senescent (p16 INK4A , SA‐β‐gal, DNA damage γH2AX, telomere length, senescence‐associated secretory phenotype [SASP]), unable to replicate, differentiate, regenerate or restore cardiac function following transplantation into the infarcted heart. SASP factors secreted by senescent CPCs renders otherwise healthy CPCs to senescence. Elimination of senescent CPCs using senolytics abrogates the SASP and its debilitative effect in vitro. Global elimination of senescent cells in aged mice (INK‐ATTAC or wild‐type mice treated with D + Q senolytics) in vivo activates resident CPCs and increased the number of small Ki67‐, EdU‐positive cardiomyocytes. Therapeutic approaches that eliminate senescent cells may alleviate cardiac deterioration with aging and restore the regenerative capacity of the heart.
Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases
Zhao, Lili , Leja, Monika, McHugh, Jonathan B. , Shango, Maryann, Baker, Laurence H. , Schuetze, Scott M. , Chugh, Rashmi , Chugh, Rashmi , Zhao, Lili , Siontis, Brittany L.

Mayo Clinic

Sarcoma | March 10, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-6

10.1155/2019/1960593 | PMID 30962762 Get It

Introduction . Primary cardiac sarcoma (PCS) has a poor prognosis compared to other sarcomas due to late presentation, challenging resection, incidence of metastases, and limited efficacy of systemic therapies. Methods . A medical record search engine was queried to identify patients diagnosed with PCS from 1992 to 2017 at the University of Michigan. Results . Thirty-nine patients with PCS had a median age of 41 years (range 2–77). Common histologies were angiosarcoma (AS, 14), high-grade undifferentiated pleomorphic sarcoma (UPS, 10), and leiomyosarcoma (LMS, 5). Sites of origin were left atrium (18), right atrium (16), and pericardium (5). AS was the most common right-sided tumor; UPS was more common on the left. Eighteen patients presented with metastases involving lung (10), bone (7), liver (5), and brain (4). Twenty-five patients underwent resection, achieving 3 R 0 resections. Patients received a median of 2 (1–6) systemic therapies. Median overall survival (OS) was 12.1 months (range 0–79). Median OS was 14.0 months and 8.2 months in patients who did or did not undergo resection, respectively ( p = 0.018 ). Brain metastases occurred in 12 (31%) patients, 9 (75%) of whom had left heart tumors, at a median of 8.5 months (range 0–75) from diagnosis. Median OS was 5.6 months (range 0–30) after the diagnosis of brain metastases. Conclusions . PCS portends a poor prognosis, because of difficulty in obtaining complete resection of sarcoma, advanced stage at diagnosis, and high risk of brain metastases. Providers should be aware of the increased risk of brain metastases and consider brain imaging at diagnosis and follow-up.
International Humanitarian Work
Eells, Annica C. , Oliver, Jeremie D. , Forte, Antonio J. , Forte, Antonio Jorge , Oliver, Jeremie D

Mayo Clinic

Annals of Plastic Surgery | March 10, 2019 | Volume: 82 | Issue: 4 | Pages: 361-362

10.1097/sap.0000000000001835 | PMID 30855363 Get It

Atypical Polyps Presenting With Occult Bleeding
Mouchli, Mohamad, Parekh, Parth J. , Grider, Douglas J.

Mayo Clinic

ACG Case Reports Journal | March 10, 2019 | Volume: 6 | Issue: 2 | Pages: e00017

10.14309/crj.0000000000000017 | PMID 31616719 Get It

Shared Decision Making for Athletes with Cardiovascular Disease: Practical Considerations
Baggish, Aaron L. , Ackerman, Michael J. , Lampert, Rachel , Baggish, Aaron L , Putukian, Margot

Mayo Clinic

Current Sports Medicine Reports | March 10, 2019 | Volume: 18 | Issue: 3 | Pages: 76-81

10.1249/jsr.0000000000000575 | PMID 30855305 Get It

The diagnosis and management of cardiovascular disease (CVD) in competitive athletes represent a fundamental responsibility of the sports medicine community. Following the diagnosis of a CVD in a competitive athlete, it is the responsibility of the sports medicine team to delineate an effective treatment and management strategy that places the health and wellness of the athlete as the primary objective. An essential and often challenging aspect of this process is determining the appropriateness of continued participation ( i.e., “return-to-play”) in competitive athletics. Recently, a joint American Heart Association and American College of Cardiology Scientific Statement delineating sports eligibility supports a more patient-centered care model that supports shared decision making for clinicians and their patients/families. The present document was written to summarize the changing sports cardiology landscape with an aim of providing the cardiology and sports medicine communities with some practical approaches to eligibility decision making for competitive athletes with heart disease.
Contribution of T-SPOT.TB Assay to the Diagnosis of Active Tuberculosis Infection among Chronic Kidney Disease Patients on Immunosuppressive Therapy
Aeddula, Narothama Reddy , Pathireddy, Samata, Thongprayoon, Charat , Cheungpasitporn, Wisit , Cheungpasitporn, Wisit , Aeddula, Narothama Reddy , Thongprayoon, Charat

Mayo Clinic

Journal of Investigative Surgery | March 9, 2019 | Volume: 33 | Issue: 9 | Pages: 859-860

10.1080/08941939.2019.1574323 | PMID 30852922 Get It

Intraoperative Management of an Enlarged Suprameatal Tubercle During Microvascular Decompression of the Trigeminal Nerve, Surgical and Anatomical Description: 2-Dimensional Operative Video
Peris‐Celda, Maria , Perry, Avital , Graffeo, Christopher S. , Link, Michael J. , Carlstrom, Lucas P.

Mayo Clinic

Operative Neurosurgery | March 9, 2019 | Volume: 17 | Issue: 6 | Pages: E247-E247

10.1093/ons/opz027 | PMID 30851049 Get It

Abstract The suprameatal tubercle is a variable prominence of the posterior aspect of the petrous part of the temporal bone located above the internal acoustic meatus. An enlarged suprameatal tubercle (EST) may present an obstacle during posterior fossa operations, including microvascular decompression (MVD). In this video we present the case of a 55-yr-old woman with 2 yr of medically refractory left V2-3 typical trigeminal neuralgia. Magnetic resonance imaging (MRI) was suspicious for a compressive superior cerebellar artery (SCA) loop, and negative for any other pathological findings. A left retrosigmoid craniotomy was performed, and upon initial exploration, only the most proximal, superior aspect of the trigeminal nerve was unobscured by an EST. The EST was subsequently removed using the ultrasonic aspirator with bone cutting attachment, allowing full visualization of the nerve from root entry zone (REZ) to Meckel's cave. Inferiorly, a small EST remnant was left to protect the VII-VIII complex. An MVD was performed using Teflon felt to elevate the SCA loop off the REZ and nerve, which was then fully explored, to ensure complete decompression. The patient recovered well with resolved trigeminal neuralgia and no new deficit. EST is a rare anatomic variant, with potentially significant implications for visualization of structures superior and deep to the internal acoustic canal, including the trigeminal REZ and nerve. Resection of the tubercle is safe, and recommended where it markedly obstructs the operative corridor. Care should be taken to wax the drilled surface of the petrous temporal bone and minimize incumbent risk of cerebrospinal fluid leak. Informed consent was appropriately documented and verified as outlined by our institutional guidelines.